N/A N=75 Personalized Text Messages to Improve Antiretroviral Treatment (ART) Adherence in HIV+ Methamphetamine Users
HIV · AIDS
Primary: Overall MEMS Adherence to Antiretroviral Medication — 68.0; 70.4 percentage of taken doses — p=0.68
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=19 Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients
Multiple Sclerosis
Primary: Total Number of Lesions Detected by [18F]Florbetapir PET — 194 Lesions
Phase 4 N=40 Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH)
Sickle Cell Disease · Renal Function Disorder
Primary: Measure of Plasmatic Data: Maximum Concentration (Cmax) — 271.8; 316.8; 260.2 Micromolar
N/A N=80 The Impacts of Theta-burst Stimulation on Children and Adolescents With Autism Spectrum Disorder
Autism Spectrum Disorder
Primary: Changes of Total Scores of Social Responsiveness Scale — 107.3; 102.1; 103.4; 100.1 score on a scale
Phase 4 N=21 The Effect of Donepezil on Gait and Balance in Parkinson's Disease
Parkinson's Disease
Primary: Sensory Organization Test - Composite Score — 7.7; 0.6 score on a scale
N/A N=54 Managing Post-operative Pain in Children With Cerebral Palsy Using a Pain Pump
Cerebral Palsy
Primary: The Amount of Oral Analgesic Each Subject Consumed Over the 4-day Study Period. — 0.34; 0.24; 0.39; 0.19 mg/kg
Phase 3 N=178 A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine
Metastasis · Breast Cancer
Primary: Overall Survival (OS) of Patients — 7.8; 7.5 months
N/A N=27 Oxygen Reserve Index (ORi) Validation of INVSENSOR00025
Healthy
Primary: Specificity for Changes in ORi Values as Compared to Corresponding Changes in PaO2 Values. — 94.82; 90.69; 100 percentage of true negatives
N/A N=22 InterventiOn of Biventricular Pacemaker Function on ventrIcular Function Among Patients With LVAD's
Heart Diseases · Left Ventricular Dysfunction
Primary: Peak Vo2 — 33; 12.5 ml/kg/min
N/A N=44 Atherectomy By Laser Ablation With Turbo-Elite
Peripheral Arterial Disease · Peripheral Vascular Disease
Primary: Primary Efficacy Endpoint - Mean Reduction in Percent Stenosis — 39 Participants
N/A N=500 Milgamma® and Milgamma® Compositum Step-therapy in Patients With Acute Non-specific Low Back Pain Receiving Modern NSAID
Acute Non-specific Low Back Pain
Primary: Change of Pain Intensity After 10 Days of Treatment — -5.1; -4.0 units on a scale — p=<0.001
N/A N=21,240 A Safety Study For Prevenar 13 Among Chinese Children
Seizures · Urticaria and Angioedema · Apnea
Primary: Incidence Rate (Per 1000 Person Days) of All Seizures Through 0 to 3 Days After Dose 1 — NA; NA Events per 1000 person-days
N/A N=58 Texting to Improve Adherence in HIV+ With Bipolar Disorder
HIV Disease · Bipolar Disorder
Primary: Proportion Adherent to ARV and Psychotropic Medication by Electronic Monitoring System (MEMS) — 90.3; 90.0; 83.9; 90.0 percentage of taken doses — p=0.95
N/A N=1,597 DUS on the Prescribing Indications for CPA/EE in 5 European Countries
Hirsutism · Androgenetic Alopecia · Severe Anemia
Primary: Drug Utilization Pattern of Cyproterone Acetate and Ethinyl Estradiol — 594; 128; 106; 769 Participants
N/A N=272 Clinical Investigation of the Safety and Effectiveness of an Investigational Model of the TECNIS® Intraocular Lens
Cataract · Corneal Astigmatism
Primary: Distance-Corrected Near Visual Acuity (DCNVA) at 40 cm — 0.104; 0.522 LogMAR — p=<0.0001